Piper Sandler Reiterates Buy Rating on DexCom, Inc. (DXCM)
Piper Sandler maintains a buy rating on DexCom with a price target of $88, a 23.54% upside from the current price.
Key Points
- Piper Sandler reiterated its buy rating on DexCom, Inc. (DXCM) with a target price of $88 on June 15, 2026.
- Piper Sandler's $88 price target implies 23.54% upside from DexCom, Inc.'s ($DXCM) current $71.23 share price.
- DexCom shares are trading near $75.37 with a market cap of about $29.08 billion and a P/E ratio of 32.35.
- Recent insider activity at DexCom includes planned sales by EVP Jon Coleman and several buys by board members.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Piper Sandler has reiterated its buy rating on DexCom, Inc. (NASDAQ: DXCM) with a price target of $88. This announcement came on June 15, 2026, as DexCom's shares traded around $75.37.
Other Institutional Activity in DexCom
Tudor Investment Corp Et Al significantly increased its holdings in DexCom by 69.1 million shares, ending with 69.2 million shares valued at approximately $63.8 million. BlackRock, Inc. trimmed its position by 884,006 shares, leaving it with about 38.9 million shares worth $2.45 billion. Vanguard Capital Management LLC maintained its stake at 25 million shares valued at $1.57 billion, while State Street Corp slightly reduced its holdings by 158,707 shares to 17.9 million shares, valued at $1.13 billion.
DexCom, Inc. Stock Down 21.6%
Shares of DexCom, Inc. (NASDAQ: DXCM) recently traded around $75.37. The company has a market capitalization of approximately $29.08 billion and a P/E ratio of 32.35, with a forward P/E of 24.45. DexCom's stock has seen a 52-week low of $54.11 and a high of $89.98. The company's beta is 1.44, indicating a higher volatility compared to the market. Its 50-day moving average is $65.87, and the 200-day moving average is $67.57.
$DXCM price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
DexCom reported revenue of $4.82 billion, reflecting a 15% growth. The company's net margin stands at 19.31%, with a return on equity of 35.62%. The next earnings report is scheduled for July 29, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
4 target cuts vs 0 raises.
-
EPS & revenue
EPS beat estimates by 17.0%. Revenue missed estimates by 0.5%.
-
Profit surprise
EBITDA beat by 5 percent. Operating income beat by 21 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
4 target cuts.
-
Earnings quality
Gross margin up 6.1 points. Operating margin up 8.5 points. Positive free cash flow.
Earnings Call Summary
DexCom delivered first-quarter revenue of $1.19 billion, up fifteen percent year over year, with strong international growth of twenty-six percent. The company achieved record global new patient starts and grew U.S. market share significantly in the type 2 non-insulin segment, driven by the G7 15-day launch and better product algorithms. Management highlighted upcoming announcements including randomized control trial results at the ADA conference and new basal insulin features designed to simplify diabetes treatment.
Guidance DexCom reaffirmed full-year revenue guidance of about $5.18 billion, representing growth of eleven to thirteen percent. The company raised full-year operating profit and EBITDA margin guidance, citing strong cost control and manufacturing improvements. Management expects continued momentum from the G7 15-day product launch and potential coverage expansion for type 2 non-insulin patients later in the year.
Clearly negative report. The company missed important expectations and likely triggers downward revisions.
Insider Buying and Selling at DexCom, Inc.
Recent insider transactions at DexCom include planned sales by EVP Jon Coleman, who sold 4,911 shares on June 4, 2026, at an average price of $74.13, and 4,912 shares on June 3, 2026, at $73. Additionally, board members Bridgette Heller, Albert Frederick Osterloh IV, Mark Foletta, and Euan Ashley each purchased shares on May 28, 2026, though the exact price was not disclosed.
Analysts Set New Price Targets
On June 15, 2026, Piper Sandler reiterated its buy rating on DexCom with an $88 price target. TD Cowen maintained a buy rating with a $95 target on June 10, while Mizuho set an $85 target on June 9. Stifel also maintained its buy rating with a $90 target on June 5. Overall, the consensus recommendation is a strong buy, with a mean target price of $84.67 among 24 analysts.
About DexCom, Inc.
DexCom, Inc., headquartered in San Diego, California, is a healthcare company in the medical devices industry. It focuses on designing and selling continuous glucose monitoring (CGM) systems for diabetes management. Key products include the Dexcom G6 and G7 CGM systems and the Dexcom ONE+ for diabetes treatment decisions. The company serves endocrinologists, physicians, and diabetes educators and employs around 11,000 people under the leadership of CEO Jacob Steven Leach.
Bottom Line
Piper Sandler's reiterated buy rating on DexCom highlights the firm's confidence in the company's growth potential. With a solid market position and a strong product line in continuous glucose monitoring, DexCom remains a noteworthy player in the healthcare sector. Investors should note that 13F filings and analyst ratings are backward-looking and may not reflect current positions or conditions.
Get DexCom, Inc. alerts
New 13F filings, insider trades, and analyst moves on $DXCM, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.